CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE
✉ Email this page to a colleague
All Clinical Trials for Acetazolamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000115 ↗ | Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema | Completed | National Eye Institute (NEI) | Phase 2 | 1990-12-01 | To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema. |
| NCT00004802 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders | Completed | Ohio State University | Phase 3 | 1992-06-01 | OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis. |
| NCT00004802 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1992-06-01 | OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis. |
| NCT00108602 ↗ | Sleep Apnea: Mechanism and Cerebrovascular Consequences | Withdrawn | US Department of Veterans Affairs | N/A | 2007-05-01 | This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography. |
| NCT00108602 ↗ | Sleep Apnea: Mechanism and Cerebrovascular Consequences | Withdrawn | VA Office of Research and Development | N/A | 2007-05-01 | This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Acetazolamide
Condition Name
Clinical Trial Locations for Acetazolamide
Trials by Country
Clinical Trial Progress for Acetazolamide
Clinical Trial Phase
Clinical Trial Sponsors for Acetazolamide
Sponsor Name
| Sponsor Name for Acetazolamide | |
| Sponsor | Trials |
| University of Zurich | 23 |
| National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov | 16 |
| University of California, San Diego | 5 |
| [disabled in preview] | 9 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
